Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 244Carcinoma, Renal Cell 144Neoplasms 99Neoplasm Metastasis 99Squamous Cell Carcinoma of Head and Neck 88Carcinoma, Hepatocellular 87Colorectal Neoplasms 82Lung Neoplasms 77Stomach Neoplasms 59Pancreatic Neoplasms 56Carcinoma, Transitional Cell 50Hodgkin Disease 47Urinary Bladder Neoplasms 42Head and Neck Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Brain Neoplasms 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Kidney Neoplasms 29Recurrence 28Multiple Myeloma 25Esophageal Neoplasms 24Uveal Melanoma 23Skin Neoplasms 23Uterine Cervical Neoplasms 22

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 34Whole-Body Irradiation 33Bortezomib 33ibrutinib 29Dexamethasone 27Tacrolimus 26Cyclosporine 25Busulfan 23Etoposide 22Melphalan 20Filgrastim 20zanubrutinib 18Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Flow Cytometry 10Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Indium 9Cyclosporins 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × Nivolumab × Clear all
NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Active not recruiting
36 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡